Scabies is a contagious parasitic skin disease caused by Sarcoptes scabiei var. hominis, posing a significant public health burden among children in developing countries. This systematic review evaluates the efficacy, pruritus resolution, recurrence, and safety of topical permethrin 5% compared with alternative or combination treatments for pediatric scabies. Following PRISMA 2020 and Cochrane principles, literature searches covered PubMed/MEDLINE, Cochrane CENTRAL, Embase, Scopus, LILACS, and clinical trial registries through 2026. Eligible studies included randomized controlled trials and controlled observational studies involving patients under 18 years. Risk of bias was assessed using Cochrane RoB 2.0 and ROBINS-I. Evidence included the SCRATCH Trial (2026; N = 1,092), a network meta-analysis by Genuino et al. (2026; 38 trials, N = 4,879), Haytoglu et al. (2025; N = 230), and the ITCHY Trial (2024; N = 100). Permethrin achieved clinical cure rates of 91.5%–94.2% and household cluster cure rates of 88.5% at Day 28, outperforming oral ivermectin at the household level (88.5% vs. 71.8%). Combination therapy ranked highest in the network meta-analysis (SUCRA 96.2%; RR 1.21). Adverse effects were generally mild and transient, with no serious events attributed to permethrin. Permethrin 5% remains an effective first-line treatment, while simultaneous household treatment helps prevent reinfestation. Combination therapy may benefit persistent or severe cases.
Copyrights © 2026